![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LRRC31 |
Gene summary for LRRC31 |
![]() |
Gene information | Species | Human | Gene symbol | LRRC31 | Gene ID | 79782 |
Gene name | leucine rich repeat containing 31 | |
Gene Alias | HEL-S-293 | |
Cytomap | 3q26.2 | |
Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q6UY01 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79782 | LRRC31 | HCC1_Meng | Human | Liver | HCC | 2.37e-21 | 7.73e-02 | 0.0246 |
79782 | LRRC31 | HCC2_Meng | Human | Liver | HCC | 4.93e-06 | 6.66e-02 | 0.0107 |
79782 | LRRC31 | HCC1 | Human | Liver | HCC | 5.10e-04 | 9.23e-01 | 0.5336 |
79782 | LRRC31 | HCC2 | Human | Liver | HCC | 4.15e-09 | 1.95e+00 | 0.5341 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LRRC31 | SNV | Missense_Mutation | c.1573N>T | p.Leu525Phe | p.L525F | Q6UY01 | protein_coding | tolerated(0.19) | possibly_damaging(0.809) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRRC31 | SNV | Missense_Mutation | c.1037N>T | p.Ser346Leu | p.S346L | Q6UY01 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LRRC31 | SNV | Missense_Mutation | c.1327N>T | p.Ala443Ser | p.A443S | Q6UY01 | protein_coding | deleterious(0.04) | possibly_damaging(0.656) | TCGA-BH-A18V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
LRRC31 | SNV | Missense_Mutation | c.892N>T | p.Gly298Cys | p.G298C | Q6UY01 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
LRRC31 | SNV | Missense_Mutation | c.1119N>G | p.Ile373Met | p.I373M | Q6UY01 | protein_coding | tolerated(0.07) | possibly_damaging(0.468) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
LRRC31 | SNV | Missense_Mutation | c.191N>T | p.Ser64Leu | p.S64L | Q6UY01 | protein_coding | tolerated(0.08) | benign(0) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
LRRC31 | SNV | Missense_Mutation | c.1162N>A | p.Glu388Lys | p.E388K | Q6UY01 | protein_coding | tolerated(0.08) | benign(0.173) | TCGA-DS-A0VM-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
LRRC31 | SNV | Missense_Mutation | novel | c.26N>T | p.Ser9Phe | p.S9F | Q6UY01 | protein_coding | tolerated(0.05) | possibly_damaging(0.671) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
LRRC31 | SNV | Missense_Mutation | c.373N>T | p.Gly125Cys | p.G125C | Q6UY01 | protein_coding | deleterious(0) | benign(0.371) | TCGA-Q1-A73P-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
LRRC31 | SNV | Missense_Mutation | novel | c.640G>A | p.Asp214Asn | p.D214N | Q6UY01 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |